Cadila Healthcare Limited

Brij Khera

Shriprakash Dhar Dwivedi

Kumar Kamlesh Singh

Dhimant Jasubhai Patel

Alpesh Pravinchandra Shah

Santosh Devidas Diwakar

Pankaj Ramanbhai Patel

Jayprakash Ajitsingh Parihar

Shri Prakash Dhar Dwivedi

Jitendra Maganbhai Gajera

Sunil Dnyaneshwar Narode

Muthaiyyan Essakimuthu Kannan

Chetan Jayantibhai Vasava

Dinesh Kumar Raikwar

Aman Trehan

Jitendra Rameshchandra Patel

Anil Kumar Shivprasad Tiwari

Alpeshkumar Pravinchandra Shah

Saurin Mukundbhai Amin

Samir Rameshbhai Gajjar

Hiteshkumar Natwarlal Suthar

The present invention relates to stable oral pharmaceutical compositions of sitagliptin base and processes for the preparation thereof.

Pharmaceutical compositions of sitagliptin

The present invention relates to an amorphous vortioxetine and salts thereof. In particular, the invention relates to a process for the preparation of an amorphous vortioxetine hydrobromide. Further, the invention also relates to a process for preparation of amorphous vortioxetine free base. The invention also relates to pharmaceutical compositions comprising an amorphous vortioxetine or hydrobromide salt thereof for oral administration for treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD).

Amorphous vortioxetine and salts thereof

The present invention relates to stable crystalline Form I of lorcaserin hydrochloride of Formula (IA) and processes for its preparation. The invention also relates to processes for the preparation of lorcaserin and pharmaceutically acceptable salts, solvates and hydrates thereof.

Processes for the preparation of lorcaserin

A crystalline Form N-1 of apixaban substantially free from one or more of: 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid; 7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-1-phenyl-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide; or methyl 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate, relative to apixaban by area percentage of HPLC and having a mean particle size equal to or greater than 100 &#x3bc;m.

Process for the preparation of apixaban

The present invention relates to pharmaceutical compositions of lurasidone or salts thereof. In particular, the invention relates to pharmaceutical compositions of lurasidone or salts thereof with one or more water-insoluble pharmaceutical excipients. The invention also relates to processes for the preparation of such compositions and use thereof for treatment of schizophrenia, bipolar disorders or senile dementia.

Pharmaceutical compositions of lurasidone

The present invention provides an amorphous form of apremilast and process for preparation thereof. The present invention also provides a pharmaceutical composition comprising an amorphous apremilast and one or more of pharmaceutically acceptable carriers, excipients or diluents used for the treatment of active psoriatic arthritis.

Amorphous form of apremilast

The present invention discloses a compound, which is alkali or alkaline earth metal salts of pitavastatin, wherein the alkali or earth metal comprise one or more of magnesium, zinc, potassium, strontium and barium.

Method of preparation of pitavastatin and pharmaceutical acceptable salts thereof

The invention provides the process for the preparation of pitavastatin and its pharmaceutically acceptable salts thereof. In particular, the invention provides a process for the preparation of stable pitavastatin calcium in crystalline form having water content less than 5% wt/wt. The present invention also provides stable crystalline form of pitavastatin calcium substantially free from crystal Form-A and use thereof for pharmaceutical compositions.

Growing community of inventors

Gujarat, India

Brij Khera